Overall, these data demonstrate that the combination of anti-PD-1 and anti-CTLA4 therapy has significant activity for CNS metastatic disease with a relatively low rate of serious CNS-specific toxicity. The gene discussed is PDCD1; the disease is metastatic neoplasm.